Phase II trial evaluating axitinib for patients with unresectable, recurrent, or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Assuntina G. Sacco(University of California San Diego), Francis P. Worden(Georgetown University), Mark E. Prince(University of Michigan), Carol R. Bradford(The Ohio State University), Jeffrey S. Moyer(Environmental Protection Agency), Jonathan B. McHugh(University of Michigan), Irina Dobrosotskaya(The University of Texas Health Science Center at San Antonio), Matthew E. Spector(Michigan Medicine), Thomas E. Carey(University of Michigan), Norman D. Hogikyan(Michigan Medicine), Gregory T. Wolf(University of Michigan), Lili Zhao(University of Michigan), Brent B. Ward(University of Michigan), Susan G. Urba(University of Michigan), Douglas B. Chepeha(University of Michigan), Scott A. McLean(National Health Service), Erin Lynn McKean(University of Michigan), Kelly M. Malloy(University of Michigan)
Cited by 2
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Validation of an instrument to measure voice-related quality of life (V-RQOL)
|Journal of Voice|1999|1.1k
CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment
|JNCI Journal of the National Cancer Institute|2005|947
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974
|Proceedings of the National Academy of Sciences|2013|833